2cureX AB (2CUREX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 3.288x

Based on the latest financial reports, 2cureX AB (2CUREX) has a cash flow conversion efficiency ratio of 3.288x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.06 Million ≈ $221.47K USD) by net assets (Skr626.00K ≈ $67.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

2cureX AB - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how 2cureX AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 2cureX AB total liabilities for a breakdown of total debt and financial obligations.

2cureX AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 2cureX AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
TENET FINTECH GROUP INC.
F:P0T
N/A
Permaju Industries Bhd
KLSE:7080
-0.004x
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
-0.181x
Crown Confectionery Co Ltd Pref
KO:26490K
-0.003x
China Natural Resources Inc
NASDAQ:CHNR
-0.048x
Absolicon Solar Collector AB Series B
ST:ABSL-B
-0.076x
Hapbee Technologies Inc
V:HAPB
0.329x
Wyncoast Industrial Park Public Company Limited
BK:WIN
-0.013x

Annual Cash Flow Conversion Efficiency for 2cureX AB (2015–2024)

The table below shows the annual cash flow conversion efficiency of 2cureX AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of 2cureX AB.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr5.10 Million
≈ $548.73K
Skr-4.63 Million
≈ $-497.83K
-0.907x +64.90%
2023-12-31 Skr12.08 Million
≈ $1.30 Million
Skr-31.22 Million
≈ $-3.36 Million
-2.585x -297.53%
2022-12-31 Skr43.03 Million
≈ $4.63 Million
Skr-27.98 Million
≈ $-3.01 Million
-0.650x -162.37%
2021-12-31 Skr74.34 Million
≈ $8.00 Million
Skr-18.43 Million
≈ $-1.98 Million
-0.248x -24.76%
2020-12-31 Skr58.86 Million
≈ $6.33 Million
Skr-11.69 Million
≈ $-1.26 Million
-0.199x +29.07%
2019-12-31 Skr28.08 Million
≈ $3.02 Million
Skr-7.86 Million
≈ $-846.29K
-0.280x -431.76%
2018-12-31 Skr13.62 Million
≈ $1.47 Million
Skr1.15 Million
≈ $123.76K
0.084x +139.30%
2017-12-31 Skr20.24 Million
≈ $2.18 Million
Skr-4.35 Million
≈ $-467.91K
-0.215x -240.95%
2016-12-31 Skr7.91 Million
≈ $851.78K
Skr1.21 Million
≈ $129.84K
0.152x +160.87%
2015-12-31 Skr8.19 Million
≈ $881.25K
Skr-2.05 Million
≈ $-220.70K
-0.250x --

About 2cureX AB

ST:2CUREX Sweden Biotechnology
Market Cap
$4.90 Million
Skr45.54 Million SEK
Market Cap Rank
#28396 Global
#643 in Sweden
Share Price
Skr1.81
Change (1 day)
-6.97%
52-Week Range
Skr0.51 - Skr5.48
All Time High
Skr28.20
About

2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.